Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 17;12(4):419-426.
doi: 10.1080/19466315.2020.1788984.

Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials

Affiliations

Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials

Mouna Akacha et al. Stat Biopharm Res. .

Abstract

Abstract-The COVID-19 pandemic has a global impact on the conduct of clinical trials of medical products. This article discusses implications of the COVID-19 pandemic on clinical research methodology aspects and provides points to consider to assess and mitigate the risk of seriously compromising the integrity and interpretability of clinical trials. The information in this article will support discussions that need to occur cross-functionally on an ongoing basis to "integrate all available knowledge from the ethical, the medical, and the methodological perspective into decision making." This article aims at facilitating: (i) risk assessments of the impact of the pandemic on trial integrity and interpretability; (ii) identification of the relevant data and information related to the impact of the pandemic on the trial that needs to be collected; (iii) short-term decision making impacting ongoing trial operations; (iv) ongoing monitoring of the trial conduct until completion, including the possible involvement of data monitoring committees, and adequately documenting all measures taken to secure trial integrity throughout and after the pandemic, and (v) proper analysis and interpretation of the eventual interim or final trial data.

Keywords: Adherence; Estimand; Intercurrent event; Missing data; Protocol deviations.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart illustrating some of the considerations provided in Section 2, together with possible actions implied by those considerations. Note that this is not a decision tree. Certain aspects (e.g., safety, operational challenges) are not covered. IE: intercurrent event; MAR: missing at random.

References

    1. Akacha, M., Bretz, F., Ohlssen, D., Rosenkranz, G., and Schmidli, H. (2017), “Estimands and Their Role in Clinical Trials,” Statistics in Biopharmaceutical Research, 9, 268–271. DOI: 10.1080/19466315.2017.1302358. - DOI
    1. Akacha, M., Bretz, F., and Ruberg, S. (2017), “Estimands in Clinical Trials—Broadening the Perspective,” Statistics in Medicine, 36, 5–19. DOI: 10.1002/sim.7033. - DOI - PubMed
    1. Brown, E. E., Kumar, S., Rajji, T. K., Pollock, B. G., and Mulsant, B. H. (2020), “Anticipating and Mitigating the Impact of COVID-19 Pandemic on Alzheimer’s Disease and Related Dementias,” The American Journal of Geriatric Psychiatry, DOI: 10.1016/j.jagp.2020.04.010. - DOI - PMC - PubMed
    1. Cawthon, P., Orwoll, E., Ensrud, K., Cauley, J. A., Kritchevsky, S. B., Cummings, S. R., and Newman, A. (2020), “Assessing the Impact of the COVID-19 Pandemic and Accompanying Mitigation Efforts on Older Adults,” The Journals of Gerontology, Series A, DOI: 10.1093/gerona/glaa099. - DOI - PMC - PubMed
    1. EMA (2020a), “Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic,” available at https://www.ema.europa.eu/.

LinkOut - more resources